Brief: Bergenbio Q2 Operating Loss Widens To NOK 50.8 Mln
21/08/2024 06:19
Aug 21 (Reuters) - Bergenbio ASA BGBIO.OL :
* BERGENBIO SECOND QUARTER RESULTS 2024: SOLID CLINICAL AND
FINANCIAL PROGRESS
* Q2 OPERATING LOSS NOK 50.8 MILLION VERSUS LOSS NOK 47.8
MILLION
YEAR AGO
* Q2 OPERATING REVENUES NOK 0 VERSUS NOK 0 YEAR AGO
Source text for Eikon: ID:nPn5Xcyn5a
Further company coverage: BGBIO.OL
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Oncoinvent ASA
See all newsBrief: Oncoinvent To Raise Up To NOK 140 Million In Private Placement
Brief: Oncoinvent H1 Operating Loss NOK 69 Mln
Brief: Oncoinvent Secures New Patent Expanding Protection For Radspherin
Brief: Oncoinvent's Shares To Be Consolidated In Ratio Of 100:1
Brief: Oncoinvent To Increase Share Capital In Connection With Settlement Of Underwriting Fee